Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance
- PMID: 28982811
- PMCID: PMC5639984
- DOI: 10.1136/bmjopen-2017-015997
Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance
Abstract
Objectives: To provide a detailed and current characterisation of funding of a representative sample clinical trials. We also aimed to develop guidance for standardised reporting of funding information.
Methods: We addressed the extent to which clinical trials published in 2015 in any of the 119 Core Clinical Journals included a statement on the funding source (eg, whether a not-for-profit organisation was supported by a private-for-profit organisation), type of funding, amount and role of funder. We used a stepwise approach to develop a guidance and an instrument for standardised reporting of funding information.
Results: Of 200 trials, 178 (89%) included a funding statement, of which 171 (96%) reported being funded. Funding statements in the 171 funded trials indicated the source in 100%, amount in 1% and roles of funders in 50%. The most frequent sources were governmental (58%) and private-for-profit (40%). Of 54 funding statements in which the source was a not-for-profit organisation, we found evidence of undisclosed support of those from private-for-profit organisation(s) in 26 (48%). The most frequently reported roles of funders in the 171 funded trials related to study design (42%) and data analysis, interpretation or management (41%). Of 139 randomised controlled trials (RCTs) addressing pharmacological or surgical interventions, 29 (21%) reported information on the supplier of the medication or device. The proposed guidance addresses both the funding information that RCTs should report and the reporting process. Attached to the guidance is a fillable PDF document for use as an instrument for standardised reporting of funding information.
Conclusion: Although the majority of RCTs report funding, there is considerable variability in the reporting of funding source, amount and roles of funders. A standardised approach to reporting of funding information would address these limitations. Future research should explore the implications of funding by not-for-profit organisations that are supported by for-profit organisations.
Keywords: funding; randomised controlled trial; role of funder.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis.Trials. 2017 Mar 14;18(1):125. doi: 10.1186/s13063-017-1872-0. Trials. 2017. PMID: 28292317 Free PMC article.
-
Self-declared stock ownership and association with positive trial outcome in randomized controlled trials with binary outcomes published in general medical journals: a cross-sectional study.Trials. 2017 Jul 26;18(1):354. doi: 10.1186/s13063-017-2108-z. Trials. 2017. PMID: 28747226 Free PMC article.
-
Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005.BMJ. 2018 Jun 6;361:k2130. doi: 10.1136/bmj.k2130. BMJ. 2018. PMID: 29875212 Free PMC article.
-
Impact of industry collaboration on randomised controlled trials in oncology.Eur J Cancer. 2017 Feb;72:71-77. doi: 10.1016/j.ejca.2016.11.005. Epub 2016 Dec 24. Eur J Cancer. 2017. PMID: 28027518 Free PMC article. Review.
-
Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.JAMA. 2011 Mar 9;305(10):1008-17. doi: 10.1001/jama.2011.257. JAMA. 2011. PMID: 21386079 Review.
Cited by
-
The quality of systematic reviews on the treatment of stage I non-small cell lung cancer for individualized decision-making: improved but further refinements are needed.J Thorac Dis. 2022 Oct;14(10):3660-3666. doi: 10.21037/jtd-22-1128. J Thorac Dis. 2022. PMID: 36389334 Free PMC article. No abstract available.
-
Cell-Based Therapies for Stroke: Are We There Yet?Front Neurol. 2019 Jun 25;10:656. doi: 10.3389/fneur.2019.00656. eCollection 2019. Front Neurol. 2019. PMID: 31293500 Free PMC article. Review.
-
Open access policies of leading medical journals: a cross-sectional study.BMJ Open. 2019 Jun 20;9(6):e028655. doi: 10.1136/bmjopen-2018-028655. BMJ Open. 2019. PMID: 31227538 Free PMC article.
-
Analysis of funding landscape for health policy and systems research in the Eastern Mediterranean Region: A scoping review of the literature over the past decade.Health Res Policy Syst. 2024 Jun 24;22(1):70. doi: 10.1186/s12961-024-01161-3. Health Res Policy Syst. 2024. PMID: 38915031 Free PMC article.
-
Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.Drugs Context. 2020 Jun 29;9:2020-4-15. doi: 10.7573/dic.2020-4-15. eCollection 2020. Drugs Context. 2020. PMID: 32655654 Free PMC article. Review.
References
-
- Mugambi MN, Musekiwa A, Lombard M, et al. Association between funding source, methodological quality and research outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics added to infant formula: a systematic review. BMC Med Res Methodol 2013;13:137 10.1186/1471-2288-13-137 - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources